U.S. markets open in 8 hours 6 minutes

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
16.55-1.06 (-6.02%)
At close: 04:00PM EST
16.55 0.00 (0.00%)
After hours: 06:03PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close17.61
Bid0.00 x 1300
Ask0.00 x 900
Day's Range16.34 - 17.57
52 Week Range15.88 - 54.21
Avg. Volume1,617,087
Market Cap2.597B
Beta (5Y Monthly)0.71
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IOVA

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Iovance Biotherapeutics, Inc.
    NKTR: Raising target price to $12.00NEKTAR THERAPEUTICS has an Investment Rating of HOLD; a target price of $12.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Insider Monkey

    Cathie Wood Portfolio: 10 Biggest Losers

    In this article, we discuss the 10 biggest losers in the stock portfolio of Cathie Wood. If you want to skip our detailed analysis of these stocks, go directly to Cathie Wood Portfolio: 5 Biggest Losers. Cathie Wood, the chief of ARK Investment Management, was one of the standout investors of 2020. Her flagship ARK […]

  • GlobeNewswire

    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SAN CARLOS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on November 18, 2021 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 168,575 shares of Iovance’s common stock to seven new non-executive employees. The awards were granted under Iovance’s 2021 Inducement Plan, which was adopted on

  • Benzinga

    Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers

    Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced data for lifileucel in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in patients with advanced cancers. Data were presented at the Society for Immunotherapy of Cancer Annual Meeting. Early-line treatment with single-agent pembrolizumab achieved an overall response rate (ORR) of 33% in patients with advanced melanoma and 17% in head and neck cancer patients. Cervical cancer patients previously treated with standard-of